What is the primary indication for Acetylcysteine in respiratory therapy?

Acetylcysteine, commonly known as a mucolytic agent, is primarily indicated in respiratory therapy for its ability to break down mucus in patients with chronic obstructive pulmonary disease (COPD) and pneumonia. It works by cleaving the disulfide bonds within mucus, which decreases its viscosity and facilitates easier expectoration. This makes it particularly useful in conditions where excessive mucus production is a problem, as it helps clear secretions from the airways, thereby improving airflow and enhancing pulmonary function.

The other options pertain to different therapeutic needs that are not the primary function of Acetylcysteine. While it may provide some supportive care in managing patients with airway irritation or inflammation, its main role is specifically in mucolytic therapy. Understanding this mechanism is crucial for respiratory therapists in selecting the appropriate medication for their patients.